Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metoprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.97 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.97 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.97 |
| ▸ | NPY1R | P25929 | 1/20 | 0.82 |
| ▸ | NPY2R | P49146 | 1/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Metoprolol SCHEMBL613510 | 1.00 | ADRB1 (0.97) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| (R)-Metoprolol SCHEMBL40918 | 0.99 | ADRB1 (1.00) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| Metoprolol SCHEMBL1561123 | 0.99 | ADRB1 (1.00) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| (S)-Metoprolol SCHEMBL121589 | 0.99 | ADRB1 (1.00) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| Metoprolol SCHEMBL4093 | 0.99 | ADRB1 (1.00) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| (S)-Metoprolol SCHEMBL6728301 | 0.97 | ADRB1 (0.97) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| Metoprolol SCHEMBL28445291 | 0.97 | ADRB1 (0.97) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| (S)-Metoprolol SCHEMBL2638035 | 0.97 | ADRB1 (0.97) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| Metoprolol SCHEMBL6126034 | 0.97 | ADRB1 (0.97) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| Metoprolol SCHEMBL2638034 | 0.97 | ADRB1 (0.97) | ADRB1ADRB2CYP2D6NR3C1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205639-B1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME (US) | 2015-12-23 | — | — | EP | claimed |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | claimed |
| WO-2012054438-A1 | ANTI-PCSK9 | SCHERING CORPORATION (US) | 2012-04-26 | — | — | WO | claimed |
| US-20110033465-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2011-02-10 | — | — | US | claimed |
| EP-2205639-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2010-07-14 | — | — | EP | claimed |
| WO-2009055783-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | claimed |
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2023-10-26 | — | — | US | disclosed |
| EP-3708179-B1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121861-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006116499-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | MICROBIA, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006102674-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006086562-A2 | PHENYLAZETIDINONE DERIVATIVES | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006086653-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033465-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | PCSK9, PCSK7, CETP | ADRB1 3264/4885ADRB2 4211/4885CYP2D6 3519/4885 |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | ADRB1 142/4885ADRB2 338/4885CYP2D6 3754/4885 |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | PCSK9, PCSK7, CETP | ADRB1 3264/4885ADRB2 4211/4885CYP2D6 3519/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | ADRB1 142/4885ADRB2 338/4885CYP2D6 3754/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | ADRB1 142/4885ADRB2 338/4885CYP2D6 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.